Table 1.
Demographics and Baseline Characteristics of Patients With NHL Enrolled in the LTF Study
| Variable/Statistics | Placebo (n = 44) | Plerixafor† (n = 123) | Total (n = 167) |
|---|---|---|---|
| Sex, n (%) | |||
| Male | 29 (66) | 85 (69) | 114 (68) |
| Female | 15 (34) | 38 (31) | 53 (32) |
| Ethnic origin, n (%) | |||
| Caucasian | 43 (98) | 118 (96) | 161 (96) |
| African-American | 0 | 1 (1) | 1 (1) |
| Asian | 1 (2) | 1 (1) | 2 (1) |
| Hispanic/Latino | 0 | 3 (2) | 3 (2) |
| Other | 0 | 0 | 0 |
| Age (y) | |||
| Mean (SD) | 58.4 (10.26) | 57.1 (9.83) | 57.4 (9.93) |
| Median | 58.5 | 59.0 | 59.0 |
| Min, Max | 27, 74 | 29, 75 | 27, 75 |
| Weight (kg) | |||
| Mean (SD) | 87.5 (21.95) | 87.3 (18.82) | 87.4 (19.63) |
| Median | 87.8 | 85.6 | 86.3 |
| Min, Max | 56.5, 178.0 | 48.6, 159.6 | 48.6, 178.0 |
| Underwent auto-HSCT following treatment and apheresis, n (%) | 42 (95) | 121 (98) | 163 (98) |
| Disease stage at baseline*, n (%) | |||
| I | 1 (2) | 6 (5) | 7 (4) |
| II | 8 (18) | 12 (10) | 20 (12) |
| III | 14 (32) | 28 (23) | 42 (25) |
| IV | 13 (30) | 54 (44) | 67 (40) |
| Missing | 8 (18) | 23 (19) | 31 (19) |
| Remission status at baseline*, n (%) | |||
| First/second CR | 25 (57) | 70 (57) | 95 (57) |
| Relapse/second PR | 17 (38) | 53 (43) | 70 (42) |
| Missing | 2 (5) | 0 | 2 (1) |
*
Baseline represents the point immediately before study drug was administered.
†
The plerixafor group included the patient initially randomized to placebo and subsequently underwent rescue with plerixafor.
Abbreviations: CR, complete remission; HSCT, hematopoietic stem cell transplantation; PR, partial remission; SD, standard deviation.